Halozyme begins clinical trial of Hylenex with morphine

By Lisa Kerner

Erie, Pa., Feb. 2 - Halozyme Therapeutics, Inc. said it has initiated and dosed the first patient in a clinical trial of subcutaneous administration of morphine with Hylenex, a liquid injectable formulation that includes recombinant human hyaluronidase (rHuPH20).

Hylenex is approved for use as a spreading agent to accelerate the delivery of fluids and drugs, according to a company news release.

The INcreased Flow Utilizing Subcutaneously-Enabled Morphine clinical trial, or Infuse-Morphine study, is designed to determine the time to maximal blood levels of morphine after subcutaneous administration with and without Hylenex, maximal blood levels after intravenous administration of morphine, and to assess safety and tolerability.

The double-blind, randomized, within-patient, placebo-controlled, crossover study will enroll up to 18 subjects.

Halozyme is a biopharmaceutical company that develops and commercializes recombinant human enzymes for infertility, ophthalmology and oncology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.